Optimizing treatment for older adults with depression.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Psychopharmacology Pub Date : 2023-11-18 eCollection Date: 2023-01-01 DOI:10.1177/20451253231212327
Maytinee Srifuengfung, Bethany R Tellor Pennington, Eric J Lenze
{"title":"Optimizing treatment for older adults with depression.","authors":"Maytinee Srifuengfung, Bethany R Tellor Pennington, Eric J Lenze","doi":"10.1177/20451253231212327","DOIUrl":null,"url":null,"abstract":"<p><p>This review presents a comprehensive guide for optimizing medication management in older adults with depression within an outpatient setting. Medication optimization involves tailoring the antidepressant strategy to the individual, ensuring the administration of appropriate medications at optimal dosages. In the case of older adults, this process necessitates not only adjusting or changing antidepressants but also addressing the concurrent use of inappropriate medications, many of which have cognitive side effects. This review outlines various strategies for medication optimization in late-life depression: (1) Utilizing the full dose range of a medication to maximize therapeutic benefits and strive for remission. (2) Transitioning to alternative classes (such as a serotonin and norepinephrine reuptake inhibitor [SNRI], bupropion, or mirtazapine) when first-line treatment with selective serotonin reuptake inhibitors [SSRIs] proves inadequate. (3) Exploring augmentation strategies like aripiprazole for treatment-resistant depression. (4) Implementing measurement-based care to help adjust treatment. (5) Sustaining an effective antidepressant strategy for at least 1 year following depression remission, with longer durations for recurrent episodes or severe presentations. (6) Safely discontinuing anticholinergic medications and benzodiazepines by employing a tapering method when necessary, coupled with counseling about the benefits of stopping them. Additionally, this article explores favorable medications for depression, as well as alternatives for managing anxiety, insomnia, allergy, overactive bladder, psychosis, and muscle spasm in order to avoid potent anticholinergics and benzodiazepines.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657532/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253231212327","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

This review presents a comprehensive guide for optimizing medication management in older adults with depression within an outpatient setting. Medication optimization involves tailoring the antidepressant strategy to the individual, ensuring the administration of appropriate medications at optimal dosages. In the case of older adults, this process necessitates not only adjusting or changing antidepressants but also addressing the concurrent use of inappropriate medications, many of which have cognitive side effects. This review outlines various strategies for medication optimization in late-life depression: (1) Utilizing the full dose range of a medication to maximize therapeutic benefits and strive for remission. (2) Transitioning to alternative classes (such as a serotonin and norepinephrine reuptake inhibitor [SNRI], bupropion, or mirtazapine) when first-line treatment with selective serotonin reuptake inhibitors [SSRIs] proves inadequate. (3) Exploring augmentation strategies like aripiprazole for treatment-resistant depression. (4) Implementing measurement-based care to help adjust treatment. (5) Sustaining an effective antidepressant strategy for at least 1 year following depression remission, with longer durations for recurrent episodes or severe presentations. (6) Safely discontinuing anticholinergic medications and benzodiazepines by employing a tapering method when necessary, coupled with counseling about the benefits of stopping them. Additionally, this article explores favorable medications for depression, as well as alternatives for managing anxiety, insomnia, allergy, overactive bladder, psychosis, and muscle spasm in order to avoid potent anticholinergics and benzodiazepines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
优化老年人抑郁症的治疗方法。
这篇综述提出了一个全面的指导,以优化老年抑郁症患者的药物管理在门诊设置。药物优化包括为个体量身定制抗抑郁药物策略,确保以最佳剂量给予适当的药物。就老年人而言,这个过程不仅需要调整或改变抗抑郁药物,还需要解决同时使用不适当药物的问题,其中许多药物具有认知副作用。本文概述了老年抑郁症药物优化的各种策略:(1)利用药物的全剂量范围,最大限度地提高治疗效果,争取缓解。(2)当使用选择性5 -羟色胺再摄取抑制剂(SSRIs)的一线治疗效果不理想时,改用其他药物(如5 -羟色胺和去甲肾上腺素再摄取抑制剂[SNRI]、安非他酮或米氮平)。(3)探索阿立哌唑等治疗难治性抑郁症的增强策略。(4)实施以测量为基础的护理,帮助调整治疗。(5)在抑郁缓解后至少持续1年有效的抗抑郁药物治疗,复发或严重的持续时间要更长。(6)安全停用抗胆碱能药物和苯二氮卓类药物,必要时采用逐渐减少的方法,并咨询停用这些药物的好处。此外,本文还探讨了治疗抑郁症的有效药物,以及治疗焦虑、失眠、过敏、膀胱过度活动、精神病和肌肉痉挛的替代药物,以避免使用强效抗胆碱能药物和苯二氮卓类药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
期刊最新文献
Geriatric psychiatry and brain health in old age Comment on: Attentional bias modification and attention control training in PTSD: a systematic review and meta-analysis Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs Corrigendum to 'Comment on: History repeating: guidelines to address common problems in psychedelic science'. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1